MGX 最新10-Q变化

相对上期新增的文字 · 来源:10-Q · 2026-08-10

• Collaboration revenue decreased $8.8 million for the three months ended June 30, 2026, as compared to the corresponding prior year period, due to decreases of $8.5 million in revenue related to the Ionis Agreement, partially due to timing of work performed and a $2.6 million cumulative catch-up adju…

• Collaboration revenue decreased $11.6 million for the six months ended June 30, 2026, as compared to the corresponding prior year period, due to decreases of $11.2 million in revenue related to the Ionis Agreement and $0.4 million in revenue related to the Affini-T Agreement.

• Total research and development expense for the three months ended June 30, 2026 was consistent with the corresponding prior year period, primarily due to decreases of $2.5 million in employee-related expenses, $0.6 million in stock-based compensation expense and $0.5 million in facilities and overhe…

• Total research and development expense decreased $5.8 million for the six months ended June 30, 2026, as compared to the corresponding prior year period, primarily due to decreases of $5.8 million in employee-related expenses, $1.4 million in facilities and overhead costs and $1.0 million in stock-b…

• Total general and administrative expense decreased $1.0 million for the three months ended June 30, 2026, as compared to the corresponding prior year period, primarily related to decreases of $0.4 million in stock-based compensation expense, $0.2 million in employee-related expenses, $0.2 million in…

相对上期删除的文字 · 来源:10-Q · 2026-05-11

• Collaboration revenue decreased $2.9 million for the three months ended March 31, 2026, as compared to the corresponding prior year period, due to decreases of $2.7 million in revenue related to the Ionis Agreement and $0.2 million in revenue related to the Affini-T Agreement.

• Research and development expenses decreased $5.8 million for the three months ended March 31, 2026, as compared to the corresponding prior year period, primarily due to decreases of $3.3 million in employee-related expenses, $1.1 million in research and development supplies and services, $0.9 millio…

• General and administrative expenses decreased $0.3 million for the three months ended March 31, 2026, as compared to the corresponding prior year period, primarily related to a decrease of $0.4 million in employee-related expenses, partially offset by an increase of $0.2 million in professional serv…

• Total other income (expense), net decreased $1.3 million for the three months ended March 31, 2026, as compared to the corresponding prior year period, primarily related to a decrease of $1.3 million in interest income.

• Since our inception, we have historically funded our operations primarily through sales of our redeemable convertible preferred units and convertible promissory notes, which generated approximately $351.7 million in aggregate gross proceeds, in addition to net proceeds of approximately $80.7 million…

相对上期新增的文字 · 来源:10-Q · 2026-08-10

• During the quarter ended June 30, 2026, no director or “officer” of the Company, as defined in Rule 16a-1(f) under the Exchange Act, adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.

相对上期删除的文字 · 来源:10-Q · 2026-05-11

• Brian C. Thomas, Ph. D., founder and member of our Board of Directors, entered into a pre-arranged stock trading plan on February 10, 2026. Dr. Thomas’s trading plan provides for the sale of up to 110,000 shares of our common stock between May 1, 2026 (subject to compliance with applicable laws rela…

• During the quarter ended March 31, 2026, no other director or “officer” of the Company, as defined in Rule 16a-1(f) under the Exchange Act, adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.